In the LEADER study, numerically fewer events of acute pancreatitis were observed with liraglutide compared with placebo, but liraglutide did increased serum amylase and lipase levels.
Liraglutide reduced the risk of T2DM in overweight or obese individuals with prediabetes, and led to greater weight loss, improvements in glycaemic control and CV risk factors, compared with placebo.
In T2DM patients with albuminuria, liraglutide treatment associates with reductions in circulating levels of CV risk biomarkers.
Dr. Jorge Plutzky, MD, discusses the ability to modulate and modify CV risk with new antidiabetic agents. The use of an SGLT2 inhibitor or a GLP1 agonist should be considered in appropriate patients with diabetes.
Liraglutide improved waist circumference, glucose parameters, plasma lipids and carotid intima media thickness in individuals with metabolic syndrome during an 18-month follow-up.
In HF patients with reduced LVEF and DM, no difference with regard to changes in LVEF was observed between the liraglutide and the placebo group. Liraglutide-treated patients did show more cardiac complications.
Semaglutide was related to a significant lower risk of the primary composite outcome death from CV causes, nonfatal MI or nonfatal stroke as compared to placebo.
Recent outcome studies have shown evidence for a CV benefit with novel antidiabetic therapies such as DPP4 inhibitors and SGLT2 inhibitors. Dr. Pratley summarises the observations and speculates on how these findings may affect treatment of patients with diabetes in the near future.
The number of acute and chronic HF patients with diabetes (DM) increased tremendously over the last decade. The prevalence of DM in these patients now ranges between 13 and 47% and is even higher in HF patients with preserved ejection fraction (25-33%). Both diseases are deleterious, and prognosis is even worse when the two co-exist. ‘Diabetes and heart failure are fatal twins’, states professor Voors.
Moderate alcohol consumption was associated with a higher CV risk in the hour after alcohol intake, and a lower CV risk after 24 hours, while heavy drinking yields continuous CV risk.
Liraglutide demonstrated superiority in reducing the primary endpoint of reducing CV death, non-fatal MI or non-fatal stroke, in T2DM patients at high CV risk in the LEADER trial.
This phase 2 trial showed significant reductions in HbA1c with the long-acting GLP-1 analogue semaglutide in type 2 diabetes.